Federal Register: FDA documents on clinical trialsOct 6, 2026
Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information
FDA is seeking public comments on approaches it is considering for early-phase trials of ibogaine drug products. Its request for information concerns trial design and safety considerations for those developing these products.
Why it matters: FDA's request puts early-phase ibogaine trial design and safety approaches up for public comment.
Regulations and guidanceTrial conduct and operationsSafety and recallsAI summary
Read at Federal Register